Topical roflumilast

Drug identity checked against registry records

Also recorded as ARQ-151 Cream 0.3%

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisNCT04286607ARQTPhase 3Completed2024-01-22Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.